Altimmune, Inc. Common Stock
ALT
ALT: Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
moreShow ALT Financials
Recent trades of ALT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ALT's directors and management
Government lobbying spending instances
-
$80,000 Jul 20, 2021 Issue: Health Issues
-
$50,000 Jul 20, 2021 Issue: Manufacturing Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$80,000 Apr 20, 2021 Issue: Health Issues
-
$40,000 Apr 20, 2021 Issue: Manufacturing Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$90,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Jan 20, 2021 Issue: Medical/Disease Research/Clinical Labs Manufacturing Health Issues Budget/Appropriations
-
$80,000 Oct 20, 2020 Issue: Health Issues
-
$40,000 Oct 20, 2020 Issue: Budget/Appropriations Manufacturing Health Issues Medical/Disease Research/Clinical Labs
-
$5,000 Jul 20, 2020 Issue: Health Issues
-
$20,000 Jul 20, 2020 Issue: Manufacturing Health Issues Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$30,000 Apr 20, 2020 Issue: Health Issues
New patents grants
-
Patent Title: Peptide pharmaceuticals for treatment of nash and other disorders Jan. 03, 2023
-
Patent Title: Coronavirus immunogenic compositions and uses thereof Jul. 12, 2022
-
Patent Title: Rapid and prolonged immunologic-therapeutic Oct. 12, 2021
-
Patent Title: Rapid and prolonged immunogic therapeutic Jun. 22, 2021
-
Patent Title: Rapid and prolonged immunologic therapeutic Jun. 22, 2021
-
Patent Title: Immunization of avians by administration of non-replicating vectored vaccines Aug. 18, 2020
-
Patent Title: Rapid and prolonged immunologic-therapeutic Jan. 22, 2019
-
Patent Title: Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax May. 15, 2018
-
Patent Title: Rapid and prolonged immunologic-therapeutic Mar. 28, 2017
-
Patent Title: Rapid and prolonged immunologic-therapeutic Nov. 03, 2015
Federal grants, loans, and purchases
Followers on ALT's company Twitter account
Number of mentions of ALT in WallStreetBets Daily Discussion
Recent insights relating to ALT
Recent picks made for ALT stock on CNBC
ETFs with the largest estimated holdings in ALT
Flights by private jets registered to ALT